Duopharma Biotech Berhad announced a year-to-date revenue of RM544.76 million and profit before tax of RM69.5 million in the current period, marking a 10.33% and 5.54% increase from the corresponding period last year. The group attributes better performance to higher demand from the public health sector and the ethical classic market contributed to the improved revenue and profit before tax.
During the quarter, the Company paid an interim dividend of 0.5 sen per share amounting to approximately RM4.76 million for the financial period. Duopharma Biotech Group Managing Director Leonard Ariff Abdul Shatar expressed optimism for satisfactory performance in 2022, in light of the strong demand from the private ethical market and public health sector, and further underpinned by positive growth momentum in Malaysia’s economy following the reopening of international borders, despite manufacturing margin pressure from a strong US dollar.
“The outlook for Duopharma Biotech is positive in light of the continued emphasis placed by the Government on the healthcare sector every year. We will continue to explore new opportunities to expand our product portfolio in the health and wellness sector as a leading pharmaceutical company in Malaysia, and strengthen our commitment to the halal sector,” Leonard Ariff said.
Recently, Duopharma Consumer Healthcare Sdn Bhd, a subsidiary of Duopharma Biotech Berhad, signed a Product Distribution Agreement with South Korea-based stem cell technology company SCM Lifesciences, Inc to distribute a range of IRORO brand halal-certified anti-hair loss products specially formulated for the Malaysian market, expanding its offerings in the cosmeceutical segment.
